Madrigal Pharmaceuticals, Inc. Board of Directors
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Dr. Rebecca A. Taub M.D.
Founder, Chief Medical Officer, President of Research & Development and Director
Leaving Board of Directors Review
Your about to visit the following url
Invalid URL
Loading...
Comments
Comment created.